Extragonadal germ cell tumors: Relation to testicular neoplasia and management options

Carsten Bokemeyer, Jörg T. Hartmann, Sophie D. Fossa, Jean P. Droz, Hans J. Schmoll, Alan Horwich, Arthur Gerl, Jörg Beyer, Jörg Pont, Lothar Kanz, Craig R. Nichols, Lawrence Einhorn, Ken Grigor, Sabine Kliesch, Tim Oliver, Peter M. Petersen, Klaus Peter Dieckmann, Gedske Daugaard, Mikael Rørth, Niels SkakkebækFinn Edler Von Eyben

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

An unselected population of 635 consecutive extragonadal GCT patients (EGCT) treated between 1975 through 1996 at 11 cancer centers was retrospectively evaluated for clinical prognosis and biological features of this disease. Five hundred twenty-four patients (83%) had a nonseminomatous GCT, and 104 patients (16%) a seminomatous histology; 341 (54%) patients had a primary mediastinal EGCT, and 283 patients (45%) a retroperitoneal EGCT. Following platinum based induction chemotherapy±secondary surgery, 141 patients (49%) with mediastinal nonseminomas (median follow up period: 19 months) and 144 patients (63%) with retroperitoneal nonseminoma (median follow up period: 29 months) are alive [p=0.0006]. In contrast, the overall survival rate for patients with seminomatous EGCT is 88% with no difference between patients with mediastinal or retroperitoneal tumor location (median follow up period: 49 months). Multivariate analysis revealed nonseminomatous histology, the presence of non-pulmonary visceral metastases, primary mediastinal GCT location, and elevated β-HCG as independent prognostic factors for shorter survival. Sixteen patients (4.1%) developed a metachronous testicular cancer despite the use of platinum based chemotherapy. The cumulative risk of developing a MTC 10-years after a diagnosis of EGCT was 10.3% (95% CI=4.9 to 15.6%), but higher among patients with nonseminomatous EGCT (14.3%; 95% CI=6.7 to 21.9%) or retroperitoneal EGCT location (14.2%; 95% CI=5.6 to 22.8%) than among patients with seminomatous EGCT (1.4%; 95% CI=0.0 to 4.2) or mediastinal EGCT location (6.2%; 95% CI=0.1 to 12.2). After a median follow-up of 51 months (range=1 to 154 months), all 16 MTC patients were alive without disease. Patients with pure seminomatous EGCT histology have a long term chance of cure of almost 90% irrespective of the primary tumor site. Patients with mediastinal nonseminomas have a five-years survival rate of 45%. This outcome is clearly inferior compared to patients with nonseminomatous retroperitoneal primaries who have a five-year survival rate of 62%.

Original languageEnglish
Pages (from-to)49-63
Number of pages15
JournalAPMIS
Volume111
Issue number1
DOIs
StatePublished - Jan 1 2003

Fingerprint

Germ Cell and Embryonal Neoplasms
Neoplasms
Histology
Survival Rate
Platinum

Keywords

  • Extragonadal germ cell tumors
  • Hematologic disorder
  • Mediastinal tumors
  • Metachronuos testicular tumor
  • Nonseminoma
  • Retroperitoneal tumors
  • Second solid tumors
  • Seminoma

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Microbiology (medical)
  • Immunology

Cite this

Bokemeyer, C., Hartmann, J. T., Fossa, S. D., Droz, J. P., Schmoll, H. J., Horwich, A., ... Von Eyben, F. E. (2003). Extragonadal germ cell tumors: Relation to testicular neoplasia and management options. APMIS, 111(1), 49-63. https://doi.org/10.1034/j.1600-0463.2003.11101081.x

Extragonadal germ cell tumors : Relation to testicular neoplasia and management options. / Bokemeyer, Carsten; Hartmann, Jörg T.; Fossa, Sophie D.; Droz, Jean P.; Schmoll, Hans J.; Horwich, Alan; Gerl, Arthur; Beyer, Jörg; Pont, Jörg; Kanz, Lothar; Nichols, Craig R.; Einhorn, Lawrence; Grigor, Ken; Kliesch, Sabine; Oliver, Tim; Petersen, Peter M.; Dieckmann, Klaus Peter; Daugaard, Gedske; Rørth, Mikael; Skakkebæk, Niels; Von Eyben, Finn Edler.

In: APMIS, Vol. 111, No. 1, 01.01.2003, p. 49-63.

Research output: Contribution to journalArticle

Bokemeyer, C, Hartmann, JT, Fossa, SD, Droz, JP, Schmoll, HJ, Horwich, A, Gerl, A, Beyer, J, Pont, J, Kanz, L, Nichols, CR, Einhorn, L, Grigor, K, Kliesch, S, Oliver, T, Petersen, PM, Dieckmann, KP, Daugaard, G, Rørth, M, Skakkebæk, N & Von Eyben, FE 2003, 'Extragonadal germ cell tumors: Relation to testicular neoplasia and management options', APMIS, vol. 111, no. 1, pp. 49-63. https://doi.org/10.1034/j.1600-0463.2003.11101081.x
Bokemeyer C, Hartmann JT, Fossa SD, Droz JP, Schmoll HJ, Horwich A et al. Extragonadal germ cell tumors: Relation to testicular neoplasia and management options. APMIS. 2003 Jan 1;111(1):49-63. https://doi.org/10.1034/j.1600-0463.2003.11101081.x
Bokemeyer, Carsten ; Hartmann, Jörg T. ; Fossa, Sophie D. ; Droz, Jean P. ; Schmoll, Hans J. ; Horwich, Alan ; Gerl, Arthur ; Beyer, Jörg ; Pont, Jörg ; Kanz, Lothar ; Nichols, Craig R. ; Einhorn, Lawrence ; Grigor, Ken ; Kliesch, Sabine ; Oliver, Tim ; Petersen, Peter M. ; Dieckmann, Klaus Peter ; Daugaard, Gedske ; Rørth, Mikael ; Skakkebæk, Niels ; Von Eyben, Finn Edler. / Extragonadal germ cell tumors : Relation to testicular neoplasia and management options. In: APMIS. 2003 ; Vol. 111, No. 1. pp. 49-63.
@article{2299e0ecf4a74a85b1d3a911f7d67230,
title = "Extragonadal germ cell tumors: Relation to testicular neoplasia and management options",
abstract = "An unselected population of 635 consecutive extragonadal GCT patients (EGCT) treated between 1975 through 1996 at 11 cancer centers was retrospectively evaluated for clinical prognosis and biological features of this disease. Five hundred twenty-four patients (83{\%}) had a nonseminomatous GCT, and 104 patients (16{\%}) a seminomatous histology; 341 (54{\%}) patients had a primary mediastinal EGCT, and 283 patients (45{\%}) a retroperitoneal EGCT. Following platinum based induction chemotherapy±secondary surgery, 141 patients (49{\%}) with mediastinal nonseminomas (median follow up period: 19 months) and 144 patients (63{\%}) with retroperitoneal nonseminoma (median follow up period: 29 months) are alive [p=0.0006]. In contrast, the overall survival rate for patients with seminomatous EGCT is 88{\%} with no difference between patients with mediastinal or retroperitoneal tumor location (median follow up period: 49 months). Multivariate analysis revealed nonseminomatous histology, the presence of non-pulmonary visceral metastases, primary mediastinal GCT location, and elevated β-HCG as independent prognostic factors for shorter survival. Sixteen patients (4.1{\%}) developed a metachronous testicular cancer despite the use of platinum based chemotherapy. The cumulative risk of developing a MTC 10-years after a diagnosis of EGCT was 10.3{\%} (95{\%} CI=4.9 to 15.6{\%}), but higher among patients with nonseminomatous EGCT (14.3{\%}; 95{\%} CI=6.7 to 21.9{\%}) or retroperitoneal EGCT location (14.2{\%}; 95{\%} CI=5.6 to 22.8{\%}) than among patients with seminomatous EGCT (1.4{\%}; 95{\%} CI=0.0 to 4.2) or mediastinal EGCT location (6.2{\%}; 95{\%} CI=0.1 to 12.2). After a median follow-up of 51 months (range=1 to 154 months), all 16 MTC patients were alive without disease. Patients with pure seminomatous EGCT histology have a long term chance of cure of almost 90{\%} irrespective of the primary tumor site. Patients with mediastinal nonseminomas have a five-years survival rate of 45{\%}. This outcome is clearly inferior compared to patients with nonseminomatous retroperitoneal primaries who have a five-year survival rate of 62{\%}.",
keywords = "Extragonadal germ cell tumors, Hematologic disorder, Mediastinal tumors, Metachronuos testicular tumor, Nonseminoma, Retroperitoneal tumors, Second solid tumors, Seminoma",
author = "Carsten Bokemeyer and Hartmann, {J{\"o}rg T.} and Fossa, {Sophie D.} and Droz, {Jean P.} and Schmoll, {Hans J.} and Alan Horwich and Arthur Gerl and J{\"o}rg Beyer and J{\"o}rg Pont and Lothar Kanz and Nichols, {Craig R.} and Lawrence Einhorn and Ken Grigor and Sabine Kliesch and Tim Oliver and Petersen, {Peter M.} and Dieckmann, {Klaus Peter} and Gedske Daugaard and Mikael R{\o}rth and Niels Skakkeb{\ae}k and {Von Eyben}, {Finn Edler}",
year = "2003",
month = "1",
day = "1",
doi = "10.1034/j.1600-0463.2003.11101081.x",
language = "English",
volume = "111",
pages = "49--63",
journal = "Acta pathologica et microbiologica Scandinavica",
issn = "0365-5555",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "1",

}

TY - JOUR

T1 - Extragonadal germ cell tumors

T2 - Relation to testicular neoplasia and management options

AU - Bokemeyer, Carsten

AU - Hartmann, Jörg T.

AU - Fossa, Sophie D.

AU - Droz, Jean P.

AU - Schmoll, Hans J.

AU - Horwich, Alan

AU - Gerl, Arthur

AU - Beyer, Jörg

AU - Pont, Jörg

AU - Kanz, Lothar

AU - Nichols, Craig R.

AU - Einhorn, Lawrence

AU - Grigor, Ken

AU - Kliesch, Sabine

AU - Oliver, Tim

AU - Petersen, Peter M.

AU - Dieckmann, Klaus Peter

AU - Daugaard, Gedske

AU - Rørth, Mikael

AU - Skakkebæk, Niels

AU - Von Eyben, Finn Edler

PY - 2003/1/1

Y1 - 2003/1/1

N2 - An unselected population of 635 consecutive extragonadal GCT patients (EGCT) treated between 1975 through 1996 at 11 cancer centers was retrospectively evaluated for clinical prognosis and biological features of this disease. Five hundred twenty-four patients (83%) had a nonseminomatous GCT, and 104 patients (16%) a seminomatous histology; 341 (54%) patients had a primary mediastinal EGCT, and 283 patients (45%) a retroperitoneal EGCT. Following platinum based induction chemotherapy±secondary surgery, 141 patients (49%) with mediastinal nonseminomas (median follow up period: 19 months) and 144 patients (63%) with retroperitoneal nonseminoma (median follow up period: 29 months) are alive [p=0.0006]. In contrast, the overall survival rate for patients with seminomatous EGCT is 88% with no difference between patients with mediastinal or retroperitoneal tumor location (median follow up period: 49 months). Multivariate analysis revealed nonseminomatous histology, the presence of non-pulmonary visceral metastases, primary mediastinal GCT location, and elevated β-HCG as independent prognostic factors for shorter survival. Sixteen patients (4.1%) developed a metachronous testicular cancer despite the use of platinum based chemotherapy. The cumulative risk of developing a MTC 10-years after a diagnosis of EGCT was 10.3% (95% CI=4.9 to 15.6%), but higher among patients with nonseminomatous EGCT (14.3%; 95% CI=6.7 to 21.9%) or retroperitoneal EGCT location (14.2%; 95% CI=5.6 to 22.8%) than among patients with seminomatous EGCT (1.4%; 95% CI=0.0 to 4.2) or mediastinal EGCT location (6.2%; 95% CI=0.1 to 12.2). After a median follow-up of 51 months (range=1 to 154 months), all 16 MTC patients were alive without disease. Patients with pure seminomatous EGCT histology have a long term chance of cure of almost 90% irrespective of the primary tumor site. Patients with mediastinal nonseminomas have a five-years survival rate of 45%. This outcome is clearly inferior compared to patients with nonseminomatous retroperitoneal primaries who have a five-year survival rate of 62%.

AB - An unselected population of 635 consecutive extragonadal GCT patients (EGCT) treated between 1975 through 1996 at 11 cancer centers was retrospectively evaluated for clinical prognosis and biological features of this disease. Five hundred twenty-four patients (83%) had a nonseminomatous GCT, and 104 patients (16%) a seminomatous histology; 341 (54%) patients had a primary mediastinal EGCT, and 283 patients (45%) a retroperitoneal EGCT. Following platinum based induction chemotherapy±secondary surgery, 141 patients (49%) with mediastinal nonseminomas (median follow up period: 19 months) and 144 patients (63%) with retroperitoneal nonseminoma (median follow up period: 29 months) are alive [p=0.0006]. In contrast, the overall survival rate for patients with seminomatous EGCT is 88% with no difference between patients with mediastinal or retroperitoneal tumor location (median follow up period: 49 months). Multivariate analysis revealed nonseminomatous histology, the presence of non-pulmonary visceral metastases, primary mediastinal GCT location, and elevated β-HCG as independent prognostic factors for shorter survival. Sixteen patients (4.1%) developed a metachronous testicular cancer despite the use of platinum based chemotherapy. The cumulative risk of developing a MTC 10-years after a diagnosis of EGCT was 10.3% (95% CI=4.9 to 15.6%), but higher among patients with nonseminomatous EGCT (14.3%; 95% CI=6.7 to 21.9%) or retroperitoneal EGCT location (14.2%; 95% CI=5.6 to 22.8%) than among patients with seminomatous EGCT (1.4%; 95% CI=0.0 to 4.2) or mediastinal EGCT location (6.2%; 95% CI=0.1 to 12.2). After a median follow-up of 51 months (range=1 to 154 months), all 16 MTC patients were alive without disease. Patients with pure seminomatous EGCT histology have a long term chance of cure of almost 90% irrespective of the primary tumor site. Patients with mediastinal nonseminomas have a five-years survival rate of 45%. This outcome is clearly inferior compared to patients with nonseminomatous retroperitoneal primaries who have a five-year survival rate of 62%.

KW - Extragonadal germ cell tumors

KW - Hematologic disorder

KW - Mediastinal tumors

KW - Metachronuos testicular tumor

KW - Nonseminoma

KW - Retroperitoneal tumors

KW - Second solid tumors

KW - Seminoma

UR - http://www.scopus.com/inward/record.url?scp=0038561139&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038561139&partnerID=8YFLogxK

U2 - 10.1034/j.1600-0463.2003.11101081.x

DO - 10.1034/j.1600-0463.2003.11101081.x

M3 - Article

C2 - 12752235

AN - SCOPUS:0038561139

VL - 111

SP - 49

EP - 63

JO - Acta pathologica et microbiologica Scandinavica

JF - Acta pathologica et microbiologica Scandinavica

SN - 0365-5555

IS - 1

ER -